AbbVie Inc (ABBV) : Tufton Capital Management reduced its stake in AbbVie Inc by 3.13% during the most recent quarter end. The investment management company now holds a total of 134,724 shares of AbbVie Inc which is valued at $8,743,588 after selling 4,353 shares in AbbVie Inc , the firm said in a disclosure report filed with the SEC on Jul 26, 2016.AbbVie Inc makes up approximately 1.74% of Tufton Capital Management’s portfolio.
Other Hedge Funds, Including , Calamos Wealth Management sold out all of its stake in ABBV during the most recent quarter. The investment firm sold 31,041 shares of ABBV which is valued $2,014,561.Meeder Asset Management Inc boosted its stake in ABBV in the latest quarter, The investment management firm added 2,453 additional shares and now holds a total of 51,193 shares of AbbVie Inc which is valued at $3,266,625. AbbVie Inc makes up approx 0.30% of Meeder Asset Management Inc’s portfolio.Strategic Advisors reduced its stake in ABBV by selling 4,126 shares or 8.23% in the most recent quarter. The Hedge Fund company now holds 45,978 shares of ABBV which is valued at $2,915,465. AbbVie Inc makes up approx 1.64% of Strategic Advisors’s portfolio.Verde Servicos Internacionais S.a. reduced its stake in ABBV by selling 19,937 shares or 11.8% in the most recent quarter. The Hedge Fund company now holds 149,073 shares of ABBV which is valued at $9,452,719. AbbVie Inc makes up approx 0.79% of Verde Servicos Internacionais S.a.’s portfolio.Douglass Winthrop Advisors boosted its stake in ABBV in the latest quarter, The investment management firm added 1,321 additional shares and now holds a total of 64,034 shares of AbbVie Inc which is valued at $4,147,482. AbbVie Inc makes up approx 0.30% of Douglass Winthrop Advisors’s portfolio.
AbbVie Inc opened for trading at $65.27 and hit $66.4 on the upside on Friday, eventually ending the session at $66.23, with a gain of 2.33% or 1.51 points. The heightened volatility saw the trading volume jump to 1,05,25,016 shares. Company has a market cap of $107,118 M.
On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.
Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.
AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.